Cargando…

Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors

BACKGROUND: Autophagy is a catabolic process, utilized constitutionally by body cells to recycle nutrients and to remove unwanted/damaged intracellular constituents. It is enhanced during periods of stress, such as starvation and hypoxia, aiding in cell survival and it is linked to major cellular pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Karim, Nagla, Gaber, Ola, Eldessouki, Ihab, Bahassi, El Mustapha, Morris, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173380/
https://www.ncbi.nlm.nih.gov/pubmed/31870123
http://dx.doi.org/10.31557/APJCP.2019.20.12.3789
_version_ 1783524439421353984
author Abdel-Karim, Nagla
Gaber, Ola
Eldessouki, Ihab
Bahassi, El Mustapha
Morris, John
author_facet Abdel-Karim, Nagla
Gaber, Ola
Eldessouki, Ihab
Bahassi, El Mustapha
Morris, John
author_sort Abdel-Karim, Nagla
collection PubMed
description BACKGROUND: Autophagy is a catabolic process, utilized constitutionally by body cells to recycle nutrients and to remove unwanted/damaged intracellular constituents. It is enhanced during periods of stress, such as starvation and hypoxia, aiding in cell survival and it is linked to major cellular processes, such as apoptosis and antigen expression. The process has been extensively studied in vitro models or tumor tissue samples with rare application on human subjects. METHODS: Plasma samples from 24 advanced solid tumor patients were collected at different time points before and after chemotherapy. Their exosomes were isolate and blotted for microtubule-associated protein-1 light chain-3 (LC-3B) protein as a marker for autophagy. All the subjects received a standard chemotherapy regimen of carboplatin- gemcitabine with chloroquine (CQ)/ hydroxychloroquine (HCQ) in chronic doses throughout their treatment period as an autophagy modulator. CQ/HCQ was given in 50 mg increments as guided by their tolerability to treatment. RESULTS: A total of 267 plasma samples were obtained for the 24 patients and processed. Each sample corresponds to a single time point. The first group included 6 patients, all received 50 mg of CQ with chemotherapy. LC-3B I was detected in their isolated exosomes, while LC3-BII was not detected in their samples. The second cohort of patients included 3 subjects who re-ceived 100mg of HCQ. They demonstrated both LC3-BI and II on day 15 after chemotherapy in one patient, and on third cycle after 24 hours in the second patient. The third cohort included 3 subjects who received 150 mg of HCQ. All cases demonstrated LC3-BI and II on first cycle of treatment after less than 24 hours. The last cohort included 8 subjects, who received a fixed dose of 100 mg of HCQ with treatment. In this cohort, we were able to detect both LC3-B isoforms on advanced time points of second and third cycles. CONCLUSION: Detection of autophagy protein LC3-B in exosomes serves as a dynamic method to monitor autophagy. It can be utilized to study the effects of anti-neoplastic agents on autophagy and mechanisms of drug resistance, however, to standardize our results a larger specimen of patients should be included.
format Online
Article
Text
id pubmed-7173380
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-71733802020-05-01 Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors Abdel-Karim, Nagla Gaber, Ola Eldessouki, Ihab Bahassi, El Mustapha Morris, John Asian Pac J Cancer Prev Research Article BACKGROUND: Autophagy is a catabolic process, utilized constitutionally by body cells to recycle nutrients and to remove unwanted/damaged intracellular constituents. It is enhanced during periods of stress, such as starvation and hypoxia, aiding in cell survival and it is linked to major cellular processes, such as apoptosis and antigen expression. The process has been extensively studied in vitro models or tumor tissue samples with rare application on human subjects. METHODS: Plasma samples from 24 advanced solid tumor patients were collected at different time points before and after chemotherapy. Their exosomes were isolate and blotted for microtubule-associated protein-1 light chain-3 (LC-3B) protein as a marker for autophagy. All the subjects received a standard chemotherapy regimen of carboplatin- gemcitabine with chloroquine (CQ)/ hydroxychloroquine (HCQ) in chronic doses throughout their treatment period as an autophagy modulator. CQ/HCQ was given in 50 mg increments as guided by their tolerability to treatment. RESULTS: A total of 267 plasma samples were obtained for the 24 patients and processed. Each sample corresponds to a single time point. The first group included 6 patients, all received 50 mg of CQ with chemotherapy. LC-3B I was detected in their isolated exosomes, while LC3-BII was not detected in their samples. The second cohort of patients included 3 subjects who re-ceived 100mg of HCQ. They demonstrated both LC3-BI and II on day 15 after chemotherapy in one patient, and on third cycle after 24 hours in the second patient. The third cohort included 3 subjects who received 150 mg of HCQ. All cases demonstrated LC3-BI and II on first cycle of treatment after less than 24 hours. The last cohort included 8 subjects, who received a fixed dose of 100 mg of HCQ with treatment. In this cohort, we were able to detect both LC3-B isoforms on advanced time points of second and third cycles. CONCLUSION: Detection of autophagy protein LC3-B in exosomes serves as a dynamic method to monitor autophagy. It can be utilized to study the effects of anti-neoplastic agents on autophagy and mechanisms of drug resistance, however, to standardize our results a larger specimen of patients should be included. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC7173380/ /pubmed/31870123 http://dx.doi.org/10.31557/APJCP.2019.20.12.3789 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Abdel-Karim, Nagla
Gaber, Ola
Eldessouki, Ihab
Bahassi, El Mustapha
Morris, John
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title_full Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title_fullStr Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title_full_unstemmed Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title_short Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
title_sort exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i study of chloroquine in combination with carboplatin/gemcitabine in advanced solid tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173380/
https://www.ncbi.nlm.nih.gov/pubmed/31870123
http://dx.doi.org/10.31557/APJCP.2019.20.12.3789
work_keys_str_mv AT abdelkarimnagla exosomesasasurrogatemarkerforautophagyinperipheralbloodcorrelativedatafromphaseistudyofchloroquineincombinationwithcarboplatingemcitabineinadvancedsolidtumors
AT gaberola exosomesasasurrogatemarkerforautophagyinperipheralbloodcorrelativedatafromphaseistudyofchloroquineincombinationwithcarboplatingemcitabineinadvancedsolidtumors
AT eldessoukiihab exosomesasasurrogatemarkerforautophagyinperipheralbloodcorrelativedatafromphaseistudyofchloroquineincombinationwithcarboplatingemcitabineinadvancedsolidtumors
AT bahassielmustapha exosomesasasurrogatemarkerforautophagyinperipheralbloodcorrelativedatafromphaseistudyofchloroquineincombinationwithcarboplatingemcitabineinadvancedsolidtumors
AT morrisjohn exosomesasasurrogatemarkerforautophagyinperipheralbloodcorrelativedatafromphaseistudyofchloroquineincombinationwithcarboplatingemcitabineinadvancedsolidtumors